Ascelia Pharma AB is pleased to invite you to listen to our Q4 and Full Year Report 2023 investor conference call tomorrow at 10:00am:
Ascelia Pharma AB’s Post
More Relevant Posts
-
Thank you HC Andersen Capital for this view on Ascelia Pharma AB investment case and the opportunities ahead following strong Phase 3 data for Orviglance. #investment #oncology
Ascelia Pharma AB (One-pager): The market is still only partly discounting likelihood of approval and successful launch of Orviglance Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma AB for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 12:35 PM 29-05-2024
-
We are excited to see Life Science Sweden share that our liver imaging drug candidate, Orviglance successfully met the primary endpoint in our Phase 3 study. #phase3study #oncology
Efterlängtad framgång för hårt prövade biotechbolaget – ”Mycket nöjda”
lifesciencesweden.se
-
Julie Waras Brogren, Deputy CEO/CFO at Ascelia Pharma AB presented at HC Andersen Capital. In her presentation Julie emphasized the commercialization potential and the distinctive opportunity for a partnership related to our lead asset, Orviglance. #commercialization #opportunity
Ascelia Pharma - Commercial and partnership strategy - Inderes
inderes.dk
-
We are pleased to see Technology Networks share our news about the strong headline results for Orviglance Phase 3 study. #headlineresults #Phase3study
Ascelia Pharma Successfully Meets Primary Endpoint With Strong Headline Results in Orviglance Phase 3 Study
technologynetworks.com
-
Join our virtual live event! Remember to register and submit your questions for the upcoming event on Monday 17 June at 10:30. Our deputy CEO Julie Waras Brogren will present the commercial and partnership strategy for Orviglance. Don't miss out! #strategy #partnership #commercial
Ascelia Pharma - Commercial and partnership strategy - Inderes
inderes.dk
-
Julie Waras Brogren, Deputy CEO/CFO at Ascelia Pharma AB presented at Redeye AB. Connect here for an opportunity to hear more about our progress on Orviglance partnering and about her experiences with key success factors for emerging pharma – keeping the patient in mind from the onset and to stay focused throughout the product journey from development to commercialization. #livercancer #unmetneed #MRI
Ascelia Pharma: Interview with Deputy CEO/CFO Julie Waras Brogren
redeye.se
-
Deputy CEO Julie Waras Brogren will present the commercial and partnership strategy for Orviglance at a virtual live event for investors on 17 June at 10.30. It is already possible to register for the presentation and submit questions in advance. Registration is open to everyone and can be done via the link: #commercialstrategy #oncology
Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma AB Pharma on 17 June 2024 at 10:30 AM. At this event Julie Waras Brogren will elaborate on the commercial strategy for Orviglance and what investors should expect in terms of partnerships. You can now sign up for the event and send it your questions:https://lnkd.in/dfuPCtH9. Ascelia Pharma is a biotech company focused on orphan oncology treatments. Ascelia Pharma develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE) Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 6/6-2024 12.34.
This content isn’t available here
Access this content and more in the LinkedIn app
-
Thank you AuntMinnie.com for featuring our successful Phase 3 results for Orviglance. The study confirmed that our contrast agent, Orviglance, significantly enhanced the visualization of focal liver lesions when compared to unenhanced MRI. #milestone #oncology #unmetneed
Ascelia highlights Orviglance phase III study results
auntminnie.com
-
Magnus Corfitzen, CEO at Ascelia Pharma AB presented at the Life Science Seminar with HC Andersen Capital. To hear his presentation and the plans ahead for Orviglance you can access the presentation here. #lifescience #oncology
Ascelia Pharma - Life Science seminar 04.06.2024
https://www.youtube.com/
Senior Director Clinical Operations | clinical operations strategy | global study management | patient, investigator, site engagement | bigger pharma, biotech
5moGreat to hear Ascelia is on track, and congratulations to the secured funding 👏👏